Publisher
Springer Berlin Heidelberg
Reference144 articles.
1. Abel S, Van der Ryst E, Muihead GJ, Rosario A, Edgington A, Weissgerber G (2003) Pharmacokinetics of single and multiple oral doses of UK-427,857 — A novel CCR5 antagonist in healthy olunteers. In: 10th conference on retroviruses and opportunistic infections. Boston, MA
2. Aghokeng AF, Ewane L, Awazi B, Nanfack A, Delaporte E, Zekeng L, Peeters M (2005) Enfuvirtide binding domain is highly conserved in non-B HIV type 1 strains from Cameroon, West Central Africa. AIDS Res Hum Retroviruses 21:430–433
3. Aquaro S, D'Arrigo R, Svicher V, Perri GD, Caputo SL, Visco-Comandini U, Santoro M, Bertoli A, Mazzotta F, Bonora S, Tozzi V, Bellagamba R, Zaccarelli M, Narciso P, Antinori A, Perno CF (2006) Specific mutations in HIV-1 gp41 are associated with immunological success in HIV-1-infected patients receiving enfuvirtide treatment. J Antimicrob Chemother 58:714–722
4. Baba M, Nishimura O, Kanzaki N, Okamoto M, Sawada H, Iizawa Y, Shiraishi M, Aramaki Y, Okonogi K, Ogawa Y, Meguro K, Fujino M (1999) A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proc Natl Acad Sci USA 96:5698–5703
5. Baba M, Miyake H, Wang X, Okamotoand M, Takashima K (2006) Isolation and characterization of human immunodeficiency virus type 1 resistant to the small-molecule CCR5 antagonist TAK-652. Antimicrob Agents Chemother 51:707–715
Cited by
26 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献